Homepage | Annals of the Rheumatic Diseases
1 day ago · Annals of the Rheumatic Diseases will be published by Elsevier from January 2025.. Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders.
Annals of the Rheumatic Diseases
Mar 16, 2023 · Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Online First - Annals of the Rheumatic Diseases
6 days ago · Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study
Top cited articles - Annals of the Rheumatic Diseases
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update 2023 ACR/EULAR antiphospholipid syndrome classification criteria Global epidemiology of systemic lupus erythematosus: a …
Authors - Annals of the Rheumatic Diseases
BMJ is committed to ensuring that all good quality research is published. Our article transfer service helps authors find the best journal for their research while providing an easy and smooth publication process. If authors agree to transfer their manuscript, all versions, supplementary files and peer reviewer comments are automatically transferred; without the need to resubmit or …
About - Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases (ARD) is an international peer review journal committed to promoting the highest standards of scientific exchange and education. It covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders.
Cure as a treatment target in rheumatoid arthritis and systemic ...
Nov 12, 2024 · The past 25 years have witnessed a remarkable revolution in outcomes for patients living with rheumatoid arthritis (RA). Historically, uncontrolled joint inflammation was commonplace leading to inexorable joint destruction, disability and mortality. In contrast, well over half of patients diagnosed with RA in the modern era can now achieve disease remission …
Efficacy of synthetic and biological DMARDs: a systematic …
Jan 14, 2022 · Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA). Methods This systematic literature review (SLR) investigated the efficacy of …
Efficacy and safety of first-line biological DMARDs in rheumatoid ...
Objective To evaluate the efficacy and safety of first-line biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) with chronic kidney disease (CKD), including those undergoing haemodialysis (HD). Methods This retrospective cohort study included 425 patients with RA prescribed their first bDMARDs at two hospitals …
2021 EULAR recommendations regarding lifestyle behaviours and …
Objectives A European League Against Rheumatism taskforce was convened to review the literature and develop recommendations on lifestyle behaviours for rheumatic and musculoskeletal diseases (RMDs). Methods Six lifestyle exposures (exercise, diet, weight, alcohol, smoking, work participation) and seven RMDs (osteoarthritis, rheumatoid arthritis, …